Sight Sciences, Inc. (NASDAQ:SGHT) CFO Sells $65,186.37 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CFO Alison Bauerlein sold 10,497 shares of the stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $6.21, for a total value of $65,186.37. Following the sale, the chief financial officer now directly owns 402,685 shares of the company’s stock, valued at $2,500,673.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Alison Bauerlein also recently made the following trade(s):

• On Friday, May 17th, Alison Bauerlein sold 13,066 shares of Sight Sciences stock. The stock was sold at an average price of $5.42, for a total value of $70,817.72.

Sight Sciences Price Performance

Sight Sciences stock traded up $0.03 during midday trading on Wednesday, reaching $6.19. The company’s stock had a trading volume of 76,060 shares, compared to its average volume of 200,831. Sight Sciences, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $9.31. The company has a debt-to-equity ratio of 0.31, a quick ratio of 12.42 and a current ratio of 13.01. The stock’s 50 day simple moving average is $6.07 and its 200 day simple moving average is $5.26. The firm has a market capitalization of $307.99 million, a PE ratio of -5.53 and a beta of 2.75.

Sight Sciences (NASDAQ:SGHT) last released its earnings results on Thursday, May 2nd. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). Sight Sciences had a negative net margin of 67.18% and a negative return on equity of 44.45%. The business had revenue of $19.27 million during the quarter, compared to analyst estimates of $18.34 million. On average, equities research analysts forecast that Sight Sciences, Inc. will post -1.13 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its position in shares of Sight Sciences by 180.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 12,076 shares of the company’s stock valued at $62,000 after buying an additional 7,764 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Sight Sciences by 51.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock valued at $141,000 after buying an additional 9,106 shares in the last quarter. State Board of Administration of Florida Retirement System purchased a new position in shares of Sight Sciences in the first quarter valued at $59,000. Federated Hermes Inc. increased its position in shares of Sight Sciences by 100.0% in the third quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock valued at $202,000 after buying an additional 30,000 shares in the last quarter. Finally, Panagora Asset Management Inc. increased its position in shares of Sight Sciences by 198.1% in the fourth quarter. Panagora Asset Management Inc. now owns 59,190 shares of the company’s stock valued at $305,000 after buying an additional 39,333 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Analyst Upgrades and Downgrades

SGHT has been the subject of several recent research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a report on Friday, May 3rd. Piper Sandler reaffirmed a “neutral” rating and set a $6.00 price target (up from $5.00) on shares of Sight Sciences in a report on Friday, May 3rd. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $4.70.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.